Bright future for biomanufacturers – European Biotechnology Magazine

Cost pressure, increased productivity of fed-batch processes, and the growing number of biologics tailored to increasingly small subpopulations are encouraging the adoption of smaller scale bioprocesses more than ever. Fifty per cent of the current clinical pipeline can be supplied from 5k or smaller bio­reactors, said Jelto Swaving, Director of Business Management at Patheon, at BPI Europe, the annual meeting of the European bio­manufacturing community – just one month before Thermo Fisher Scientific announced that it will acquire the world-largest CDMO for US$7.2bn. According to David Radspinner, General Manager, BioPark, GE Healthcare, 80%…